INTRODUCTION
============

Idiopathic sudden sensorineural hearing loss (ISSHL) is characterized by a sensorineural hearing loss of at least 30 dB and at least three consecutive frequencies, which are noticed in 3 days or less \[[@b1-ceo-2019-00283]\]. Sudden hearing loss is one of the otological emergencies. Although the recovery rate is high, there may be partial or no improvement in some cases. In patients with hearing loss, social life and daily activities are negatively affected and patients experience social isolation and depression \[[@b2-ceo-2019-00283],[@b3-ceo-2019-00283]\].

Calprotectin, a member of the S100 protein family known as MRP8/MR14, S100A8/S100A9 and calgranulin, is one of the major antimicrobial human leukocyte protein. Calprotectin has bacteriostatic properties \[[@b4-ceo-2019-00283]\]. Depending on inflammation, calprotectin reaches the bloodstream through the neutrophil activation or epithelial adhesion of monocytes, so that the elevated calprotectin value in the serum can be used as a strong clinical marker indicating the presence of inflammation \[[@b5-ceo-2019-00283]\]. Studies have shown that calprotectin has a strong proinflammatory effect \[[@b6-ceo-2019-00283],[@b7-ceo-2019-00283]\]. It has also been shown that calprotectin is also elevated in pathological tissue in the case of inflammation \[[@b8-ceo-2019-00283]\]. In many inflammatory and autoimmune diseases such as larynx, stomach, lung, endometrial cancers, the expression and release of calprotectin increase \[[@b4-ceo-2019-00283]\].

There is no serum biomarker to determine the prognosis of ISSHL. The aim of this study was to determine the serum calprotectin level in ISSHL patients and to investigate the role of serum calprotectin in determining the prognosis of ISSHL patients.

MATERIALS AND METHODS
=====================

Our study is a prospective, cross-sectional historical cohort study. Our study was approved by the local Ethics Committee and carried out in accordance with the ethical principles of the Declaration of Helsinki (project no. E-17-1634). In the study, patients with unilateral ISSHL were included in the study group, and healthy volunteers with normal bilateral hearing functions were included in the control group. Written informed consent was obtained from all participants.

Patients with any autoimmune disease, a history of acute or chronic infection or symptoms of infection, hypertension, conductive hearing loss, angina pectoris, myocardial infarction, diabetes mellitus, metabolic syndrome, chronic obstructive pulmonary disease, amyloidosis, chronic renal failure, obstructive sleep apnea, active smoking or otological diseases were excluded from the study. The control group consisted of healthy volunteers without ear pathology and with normal audiological findings who applied to our center's health board before application for employment presenting their health status to their employer. The control group did not have any systemic disorders as the study group.

The audiometric examinations were performed in quiet chambers by an Interacoustics AC-40 (Denmark) clinical audiometer according to the manufacturer's instructions, and all tests were performed by the same audiometrist. Audiological data were reported according to the recommended methods of the Hearing Committee at the American Academy of Otolaryngology-Head and Neck Surgery, which has approved a new minimum standard for reporting hearing results in clinical studies \[[@b9-ceo-2019-00283]\]. Patients with ISSHL had at least 30 dB hearing loss at three consecutive frequencies, which was not associated with other known pathologies, including Meniere's disease, autoimmune disease, ototoxicity, or neoplasm developing within 72 hours of the onset of complaints. Hearing loss was unilateral in all patients.

All patients were treated with a standard ISSHL protocol containing an oral prednisone dose of 1 mg/kg per day (maximum dose 80 mg) the first 7 days, followed by gradual drug tapering in the next 7 days. Before the treatment, the patients with a hearing loss depending on ISSHL were divided into three classes as mild at a pure tone average (PTA) of less than 40 dB, moderate between 40 and 80 dB, and severe over 80 dB \[[@b10-ceo-2019-00283]\]. The response of the patients to the treatment was classified as follows (according to the recovery observed in a 1-month followup): (1) recovered: the posttreatment hearing loss value less than 10 dB compared to the initial hearing loss value or the intact ear PTA; (2) partially recovered: the posttreatment hearing loss value of more than 10 dB compared to the initial PTA or the intact ear PTA and recovery of more than 50%; (3) unrecovered: the recovery less than 10 dB compared to the initial PTA \[[@b1-ceo-2019-00283]\].

Age, sex, serum calprotectin value, the neutrophil-to-lymphocyte ratio (NLR) and other laboratory data were recorded for all groups. Serum calprotectin levels and NLR values were also compared between the groups. At the same time, the relationship between serum calprotectin values was evaluated according to the severity of hearing loss and response to treatment for ISSHL patients.

Serum calprotectin value was measured in the venous blood taken from the patients before start of treatment to rule out an influence of treatment on the laboratory vales. Cytometry scattergrams were obtained within 2 hours of blood sampling. Calprotectin measurement was performed on the ChemWell 2900 (Awareness Technology, Palm City, FL, USA) enzyme-linked immunosorbent assay (ELISA) device using the Human CALP (calprotectin) ELISA kit. Results were reported in ng/mL. Intraassay and Interassay CV% (coefficient variation) values are given as 3.92 and 4.76, respectively. All samples were analyzed in pairs, and the mean values were used for statistical values.

Statistical data analysis was performed using IBM SPSS ver. 21.0 (IBM Corp., Armonk, NY, USA). Data were expressed as mean±standard deviation (SD) for data with normal distribution, and median (minimum--maximum) for data without normal distribution. Shapiro-Wilk tests were used to check normality assumption for all parameters. Student *t*-test was used for independent samples to analyze serum calprotectin, and NLR value. The Mann-Whitney *U*-test was used to compare the groups without normal distribution. Correlations between the variable pairs were analyzed using the Pearson correlation test. A P-value \<0.05 was accepted as statistically significant.

RESULTS
=======

There were 44 patients in the study group (male: n=23, 52.3%; female: n=21, 47.7%) and 41 volunteers in the control group (male: n=20, 48.8%; female: n=21, 51.2%). A total of 85 individuals were included in the study. The mean age of the study and control groups were 43.4±14.7 years and 38.8±14.1 years, respectively. There was no statistically significant difference between the groups in terms of sex and age (*p*=0.726 and *p*=0.180, respectively) ([Table 1](#t1-ceo-2019-00283){ref-type="table"}).

The laboratory data of the study and control groups are presented in [Table 1](#t1-ceo-2019-00283){ref-type="table"}. The mean serum calprotectin value was 75.67± 19.48 ng/mL in the study group and 50.24±29.14 ng/mL in the control group, and the difference was statistically significant (*p*=0.001) ([Table 1](#t1-ceo-2019-00283){ref-type="table"}). The mean NLR value was 3.44±2.54 in the study group and 2.04±0.64 in the control group (*p*=0.002).

Serum calprotectin levels were found to be 66.20±8.82 ng/mL in patients with mild hearing loss and 70.35±16.77 ng/mL in patients with moderate hearing loss and 91.23±19.73 ng/mL in patients with severe hearing loss. Serum calprotectin levels were significantly higher in patients with severe hearing loss than those with moderate and mild hearing loss (*p*=0.004; *p*=0.001, respectively) ([Table 2](#t2-ceo-2019-00283){ref-type="table"}). NLR were found to be 2.09±0.90 ng/mL in patients with mild hearing loss and 3.88±2.82 ng/mL in patients with moderate hearing loss and 3.03±2.19 ng/mL in patients with severe hearing loss (*p*=0.251) ([Table 2](#t2-ceo-2019-00283){ref-type="table"}).

The mean value of serum calprotectin in patients with ISSHL was 85.33±22.33 in the unrecovered group, 80.17±12.06 in the partially recovered group, and 63.36±11.54 in the recovered group. The difference between the groups was statistically significant (*p*=0.001) ([Table 3](#t3-ceo-2019-00283){ref-type="table"}). The NLR in patients with ISSHL was 2.94±1.93 in the unrecovered group, 3.89±2.69 in the partially recovered group, and 3.66±3.08 in the recovered group. The difference between the groups was not statistically significant (*p*=0.566) ([Table 3](#t3-ceo-2019-00283){ref-type="table"}).

The serum calprotectin levels in patients with moderate hearing loss is increased by 4.0 units compared to those with mild hearing loss (95% confidence interval \[CI\], 1.379 to 6.621; *p*= 0.004). The serum calprotectin levels in patients with severe hearing loss is increased by 25.538 units compared to those with mild hearing loss (95% CI, 11.666 to 28.411; *p*\<0.001; R²=0.912) ([Table 4](#t4-ceo-2019-00283){ref-type="table"}).

The serum calprotectin levels in patients with partial recovery is decreased by 4.812 units compared to unrecovered group (95% CI, --9.011 to --0.612; *p*=0.026). The serum calprotectin levels in patients with recovery hearing loss is decreased by 21.529 units compared to unrecovered group (95% CI, --25.144 to --17.915; *p*\<0.001; R2=0.780) ([Table 5](#t5-ceo-2019-00283){ref-type="table"}).

DISCUSSION
==========

Serum calprotectin levels were found higher in patients with ISSHL than healthy participants, and higher in patients with severe ISSHL than in other ISSHL patients. Serum calprotectin value was found to be higher in ISSHL patients who did not respond to treatment compared to other ISSHL patients.

Calprotectin proteins account for about 45% of all cytosolic proteins in neutrophils and about 5% of all monocyte/macrophage proteins \[[@b8-ceo-2019-00283]\]. Calprotectin proteins have been reported to interact with heparan sulfate proteoglycans such as perlecan, agrin and collagen XVIII on extracellular matrix components. When monocytes and neutrophils adhere to the vascular endothelium, they release S100A8/A9 proteins to the endothelium \[[@b8-ceo-2019-00283]\]. Studies on calprotectin show that it is a biomarker that can be used for the early diagnosis of various cancers \[[@b4-ceo-2019-00283],[@b11-ceo-2019-00283]\]. However, it is thought that the concentration of calprotectin increases due to the inflammatory response in cancerous tissues \[[@b4-ceo-2019-00283]\]. In addition, calprotectin inhibits intracellular enzymes involved in cellular proliferation and creates an apoptosis-inducing effect. Calprotectin also inhibits matrix metalloproteinase, which plays a role in the growth and metastasis of cancer cells \[[@b12-ceo-2019-00283]\].

In the study of Masuda et al. \[[@b13-ceo-2019-00283]\], it was reported that neutrophil and inflammatory marker levels were higher in SHL patients than the healthy population. In another study, SHL patients were classified as mild (\<40 dB loss for any frequency), moderate (40--80 dB) and severe (\>80 dB) according to the severity of hearing loss, and the mean NLR values in SHL patients were compared with healthy individuals. The mean NLR values were found to be significantly higher in patients with severe sensorineural hearing loss than in healthy individuals \[[@b10-ceo-2019-00283],[@b14-ceo-2019-00283]\]. In our study, we found that NLR is insufficient to determine the severity of ISSHL. We divided the severity of ISSHL into three groups as mild, moderate and severe, and we investigated the relationship between calprotectin, the severity of disease and the healthy volunteer control group. As a result of the present study, we found a statistically significant difference in calprotectin value between the control group and the patient group. We also observed that serum calprotectin levels were significantly higher in patients with severe hearing loss compared to patients with moderate and mild hearing loss and there was a significant correlation between severity of disease and serum calprotectin values. Unlike NLR, serum calprotectin value can be used to determine the severity of ISSHL biomarker. In our study, we used the more common classification in meta-analysis studies and the latest treatment guidelines to evaluate the recovery criteria \[[@b1-ceo-2019-00283],[@b15-ceo-2019-00283]\] and found that serum calprotectin value in the unrecovered group was significantly higher compared to the partially recovery and recovery groups. Hence, we think that serum calprotectin value is a biomarker that can be used to determine the response of ISSHL patients to treatment. In this way, prognosis of disease can be estimated before starting treatment, and other treatment options, such as intratympanic injection or hyperbaric oxygen therapy, can be combined with steroid treatment in patients with high pretreatment calprotectin values.

Hearing impaired individuals often have difficulty in hearing background noise and identifying sound sources. It was reported that the incidence of severe depressive disorder is higher in the hearing impaired patients than in the general population \[[@b16-ceo-2019-00283]\]. Consistently with this hypothesis, depressive disorder is more common in patients who do not recover after ISSHL \[[@b3-ceo-2019-00283]\]. The current evidence suggests that psychological disorders such as depression and anxiety have a negative effect on the quality of life of patients with SSHL \[[@b3-ceo-2019-00283]\]. The authors of this study reported that clinicians increased the risk of ISSHL to develop affective disorders in patients, suggesting that special measures should be taken to reduce the risk of depression and anxiety disorder \[[@b3-ceo-2019-00283]\]. In our study, we planned to use serum calprotectin as a biomarker in order to detect patients with worse prognosis earlier during the onset of hearing loss. At the end of our study, we found that serum calprotectin is correlated with the severity of ISSHL. In patients with ISSHL, it is possible to estimate the response of the disease to treatment by examining the serum calprotectin value obtained before treatment, in this way we can inform patients about the prognosis of disease.

Our study suggests that serum calprotectin value informs the clinician about both the severity of ISSHL disease and the response to ISSHL treatment. Serum calprotectin can be used as an important prognostic biomarker in ISSHL patients for the estimation of response to treatment. This issue should be investigated on more patients in a multicenter study.

HIGHLIGHTS
==========

▪ Serum calprotectin levels were found higher in patients with idiopathic sudden sensorineural hearing loss (ISSHL) than healthy participants, and higher in patients with severe ISSHL than in other ISSHL patients.

•Serum calprotectin value was found to be higher in ISSHL patients who did not respond to treatment compared to other ISSHL patients.

•Serum calprotectin value seems to be a significant prognostic marker for the determination of response to treatment in ISSHL.
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###### 

Intergroup comparison of age, sex, serum calprotectin and NLR values of the patients and the control group

  Variable               Patient (n=44)   Control (n=41)   *P*-value
  ---------------------- ---------------- ---------------- -----------
  Age (yr)               40 (18--65)      38 (18--60)      0.180
  Sex                                                      0.726
   Female                21 (47.7)        21 (51.2)        
   Male                  23 (52.3)        20 (48.8)        
  WBC (10^3^/U)          6.9 (5.2--8.3)   6.8 (5.6--8.5)   0.790
  Platelet (10^3^/U)     262.26±3.62      268.61±55.53     0.632
  Neutrophil (10^3^/U)   4.2 (3.1--5.4)   3.5 (2.9--5.7)   0.031
  Lymphocyte (10^3^/U)   1.9 (1.5--2.6)   2.1 (1.5--2.3)   0.284
  NLR                    3.44±2.54        2.04±0.64        0.002
  Calprotectin (ng/mL)   75.67±19.48      50.24±29.14      0.001

Values are presented as median (range), number (%), or mean±standard deviation.

NLR, neutrophil-to-lymphocyte ratio; WBC, white blood cell.

###### 

Relationship between serum calprotectin levels and severity of hearing loss

  Variable               Mild (n=9)   Moderate (n=22)   Severe (n=13)   *P*-value
  ---------------------- ------------ ----------------- --------------- --------------------------------------------------------
  NLR                    2.09±0.90    3.88±2.82         3.03±2.19       0.251
  Calprotectin (ng/mL)   66.20±8.82   70.35±16.77       91.23±19.73     0.001^[a)](#tfn1-ceo-2019-00283){ref-type="table-fn"}^

Values are presented as mean±standard deviation.

NLR, neutrophil-to-lymphocyte ratio.

Mild vs. moderate, *P*=0.249; moderate vs. severe, *P*=0.004; mild vs. severe, *P*=0.001.

###### 

Comparison of laboratory data between the unrecovered, partially recovered, and recovered patients

  Variable               Unrecovered (n=17)   Partially recovered (n=10)   Recovered (n=17)   *P*-value
  ---------------------- -------------------- ---------------------------- ------------------ --------------------------------------------------------
  NLR                    2.94±1.93            3.89±2.69                    3.66±3.08          0.566
  Calprotectin (ng/mL)   85.33±22.33          80.17±12.06                  63.36±11.54        0.001^[a)](#tfn2-ceo-2019-00283){ref-type="table-fn"}^

Values are presented as mean±standard deviation.

NLR, neutrophil-to-lymphocyte ratio.

Unrecovered vs. partially recovered, *P*=0.436; partially recovered vs. recovered, *P*=0.002; unrecovered vs. recovered, *P*=0.001.

###### 

Results of regression analysis for the severity of hearing loss and serum calprotectin value

  Severity of hearing loss   B (SE)           95% CI             *P*-value
  -------------------------- ---------------- ------------------ -----------
  Moderate                   4.0 (1.298)      1.379 to 6.621     0.004
  Severe                     25.538 (1.423)   11.666 to 28.411   \<0.001

B, unstandardized beta; SE, standard error; CI, confidence interval.

###### 

Result of regression analysis for the response to treatment and calprotectin value

  Calprotektin       B (SE)             95% CI                 *P*-value
  ------------------ ------------------ ---------------------- -----------
  Partial recovery   --4.812 (2.079)    --9.011 to --0.612     0.026
  Recovery           --21.529 (1.790)   --25.144 to --17.915   \<0.001

B, unstandardized beta; SE, standard error; CI, confidence interval.
